CAMP4 Therapeutics Corporation (CAMP)

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 to Participate in Upcoming Investor Conferences

Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec

Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

New Strong Sell Stocks for July 16th